Keywords: gsk, settle, relafen, antitrust, litigation, glaxosmithkline, world
GSK to settle Relafen antitrust litigation
Article | 16 February 2004
GlaxoSmithKline, the world's second-largest drugmaker, has agreed to settle a US antitrust case involving the non-steroidal anti-inflammatory product Relafen (nabumetone). ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
